AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Monday 9 November 2026
News from the 24 hours to Monday morning, 9 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on AstraZeneca's $10 billion Rhythm acquisition, seen as a push into rare obesity and metabolic disease. Reports of nine-month growth and a cancer testing campaign added a modestly positive tone.
What drove it
- Rhythm acquisition
- nine-month growth
- cancer testing campaign
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Tue 3 Nov | +7.5 | 28 |
| Wed 4 Nov | +5.0 | 19 |
| Thu 5 Nov | +6.3 | 24 |
| Fri 6 Nov | +4.0 | 37 |
| Sat 7 Nov | +4.5 | 9 |
| Sun 8 Nov | +6.0 | 7 |
| Mon 9 Nov | +5.3 | 4 |
| Tue 10 Nov | +5.5 | 12 |
| Wed 11 Nov | +6.3 | 22 |
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
3 stories · 4 headlines · strongest first
Pharma and healthcare on 9 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca reportedly bids $10bn for Rhythm Pharmaceuticals +3.82 headlines today · 39 in all, since 5 November · Coverage describes the $10bn Rhythm acquisition and its rare obesity market focus. | ||
| +5.0 | Large acquisition expands its presence in rare obesity treatment. | |
| +4.2 | Analysis of strategic move into rare metabolic disease via Rhythm purchase. | |
| AstraZeneca shares approach Monday meetings following nine-month growth +6.71 headline today · A piece looks at AstraZeneca shares after nine-month growth. | ||
| +6.7 | Nine-month growth noted ahead of investor meetings. | |
| AstraZeneca cancer testing awareness campaign +3.11 headline today · 3 in all · AstraZeneca launched a campaign targeting a cancer testing gap. | ||
| +3.3 | Awareness campaign aimed at improving cancer testing uptake. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.